US7140461093 - Common Stock
PERKINELMER INC
NYSE:PKI (5/15/2023, 7:04:00 PM)
After market: 115.24 0 (0%)115.24
-1.06 (-0.91%)
PerkinElmer, Inc. engages in the provision of products, services, and solutions for diagnostics, food, environmental, life sciences, and applied markets. The company is headquartered in Waltham, Massachusetts and currently employs 16,700 full-time employees. The firm operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides products and services targeted towards the life sciences and applied markets. The Diagnostics segment develops diagnostics, tools and applications focused on clinically oriented customers, especially within the reproductive health, immunodiagnostics and applied genomics markets. Its products and services for Discovery & Analytical Solutions applications include The Opera Phenix Plus high-content screening system, The Operetta CLS high-content analysis system, The MuviCyte live-cell imaging system, and The Signals Image Artist. Its products and services for Diagnostics applications include The DELFIA Xpress screening platform, The Specimen Gate informatics data management solution and The DELFIA Xpress sFlt-1 kit.
PERKINELMER INC
940 Winter Street
Waltham MASSACHUSETTS 02451
P: 17816635776.0
CEO: Prahlad Singh
Employees: 16700
Website: https://www.perkinelmer.com/
Revvity (PKI) is down 5% in Thursday afternoon trading after its 2023 guidance ranges for EPS and revenue missed consensus estimates. Read more here.
PerkinElmer press release (PKI): Q1 Non-GAAP EPS of $1.01 misses by $0.01.Revenue of $674.86M (-29.9% Y/Y) misses by $3.75M.The company’s stock ticker will change from PKI to RVTY...
Here you can normally see the latest stock twits on PKI, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: